-- Reflects ongoing commitment to leverage innovation
potential between consulting, integrated clinical research and
technology-driven services
BOSTON, Feb. 12, 2014 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that
Perceptive Informatics, the PAREXEL subsidiary that provides the
Perceptive MyTrials® eClinical platform and other advanced clinical
development technology solutions, has been rebranded PAREXEL
Informatics. The Perceptive brand will be used to identify specific
PAREXEL Informatics offerings, including the Perceptive MyTrials®
eClinical platform, the Perceptive® Partner Program and the
Perceptive® Institute.
This alignment further supports the Company's ability to meet
growing demand from biopharmaceutical companies for integrated
services, as well as underscoring PAREXEL's unique ability to offer
a more seamless, fully unified, end-to-end technology and services
portfolio to clients around the world.
"As biopharmaceutical companies increasingly seek a combination
of solutions from a single service provider, we are more closely
integrating our clinical research and technology offerings to meet
this need," said Mark A. Goldberg,
President and Chief Operating Officer, PAREXEL. "Toward that end,
the new PAREXEL Informatics branding communicates our commitment to
providing technology-driven solutions that complement our other
clinical trial services, without changing our overall go-to-market
strategy. At the same time, we'll continue to use the
respected Perceptive® brand with certain offerings in recognition
of the considerable market equity it has earned over the
years."
PAREXEL Informatics is a leading eClinical solutions provider
that provides flexible Software-as-a-Service (SaaS) applications
and leading technology services to accelerate the drug development
process.
"As bringing new drugs to market becomes more complex,
particularly in today's global market, companies are relying more
on technology to gain a competitive advantage," said Xavier
Flinois, President of PAREXEL Informatics. "PAREXEL Informatics
helps our clients worldwide simplify and accelerate the drug
development process by offering industry-leading technology and
services in the context of PAREXEL's deep clinical expertise and
global reach."
The new PAREXEL Informatics name is part of the Company's
recently announced global corporate branding campaign designed to
promote the Company's ability to simplify drug development for
clients. The initiative includes the launch of PAREXEL's new
brand promise, "Your Journey. Our Mission.™", and a redesigned
corporate website that provides an enhanced visitor
experience and distinguishes PAREXEL's capabilities in a more
client-centric manner.
About PAREXEL International
PAREXEL
International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based
contract research, consulting, medical communications, and
technology solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 76 locations in 50
countries around the world, and has 15,100 employees. For
more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials,
Perceptive Informatics, and "Your Journey. Our Mission." are
trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended December 31, 2013 as filed with
the SEC on January 31, 2014, which
"Risk Factors" discussion is incorporated by reference in this
press release. The Company specifically disclaims any
obligation to update these forward-looking statements in the
future. These forward-looking statements should not be relied
upon as representing the Company's estimates or views as of any
date subsequent to the date of this press release.
Contacts:
Diana Martin, Vice President,
Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1-617-502-4300
Email: PAREXEL@pancomm.com